A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.
Yutaka SeinoHideaki MiyoshiHeidrun Bosch TrabergT V S DivyalasyaKeiji NishijimaYasuo TerauchiPublished in: Journal of diabetes investigation (2022)
levels after 26 weeks treatment vs 0.9 mg in Japanese patients, with both doses well tolerated.
Keyphrases